Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression
Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression
复制标题
DOI:
10.1016/j.jare.2023.04.013
复制
发表时间:
2024-02-28
影响因子:
10.7
通讯作者:
Zhuang,Yuan
中科院分区:
文献类型:
--
作者:
Lv,Yipin;Tian,Wenqing;Zhuang,Yuan
IntroductionIn solid tumors, regulatory T cell (Treg) and mast cell perform different roles depending on the microenvironment. Nevertheless, mast cell and Treg-mediated interactions in gastric cancer (GC) are unclear, as are their regulation, function, and clinical significance.ObjectiveThe present study demonstrated the mechanism of tumor-infiltrating mast cells stimulating ICOS+regulatory T cells via the IL-33/IL-2 axis to promote the growth of gastric cancer.MethodsAnalyses of 98 patients with GC were conducted to examine mast cell counts, ICOS+Tregs, and the levels of IL-33 or IL-2. Isolated ICOS+Treg and CD8+T cell were stimulated, cultured and tested for their functional abilitiesin vitroandin vivo.ResultsGC patients exhibited a significantly more production of IL-33 in tumors. Mast cell stimulated by tumor-derived IL-33 exhibited a prolonged lifespan through IL-33 mediated inhibition of apoptosis. Moreover, mast cells stimulated by tumor-derived IL-33 secreted IL-2, which induced Treg expansion. These inducible Tregs displayed an activated immunosuppressive phenotype with positive expression for the inducible T cell co-stimulator (ICOS). In vitro, IL-2 from IL to 33-stimulated mast cells induced increased numbers of ICOS+Tregs with increased immunosuppressive activity against proliferation and effector function of CD8+T cell. In vivo, ICOS+Tregs were treated with anti-IL-2 neutralizing antibody followed by co-injection with CD8+T cells in GC mouse model, which showed an increased CD8+T cell infiltration and effector molecules production, meanwhile tumor growth and progression were inhibited. Besides, reduction in GC patient survival was associated with tumor-derived ICOS+Tregs.ConclusionOur results highlight a crosstalk between GC-infiltrating mast cells and ICOS+Tregs and provide a novel mechanism describing ICOS+Treg expansion and induction by an IL-33/mast cell/IL-2 signaling axis in GC, and also provide functional evidence that the modulation of this immunosuppressive pathway can attenuate GC-mediated immune tolerance.